IDYA250117P35000
- 9.75
- 0.000.00%
IDEAYA Biosciences Newsroom
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $55
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and IDEAYA Biosciences (IDYA)
IDEAYA Biosciences (IDYA) Receives a Hold From Leerink Partners
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
IDEAYA Biosciences Analyst Ratings
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
IDEAYA Biosciences: Promising Pipeline and Strong Financials Make for a Buy Recommendation
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Stephens Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51
IDEAYA Biosciences Analyst Ratings
Stephens & Co. Initiates Coverage On IDEAYA Biosciences With Overweight Rating, Announces Price Target of $51
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
IDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy Rating
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $64
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61